Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 12, 2016 09:07 ET | Source: Societal CDMO, Inc.

Recro Pharma Reports First Quarter 2016 Financial Results

Enrollment on track in two pivotal Phase III IV meloxicam trials One trial expected to report top-line results by end of Q3; Other trial to report top-line results by end of Q4 Manufacturing...
May 12, 2016 09:00 ET | Source: Societal CDMO, Inc.

Recro Pharma Presents Clinical Data at American Pain Society 35th Annual Scientific Meeting

MALVERN, Pa., May 12, 2016 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company developing non-opioid products for the treatment of serious...
March 24, 2016 08:19 ET | Source: Societal CDMO, Inc.

Recro Pharma Reports Year End 2015 Financial Results

MALVERN, Pa., March 24, 2016 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company developing multiple non-opioid therapeutics for the...
March 07, 2016 08:00 ET | Source: Societal CDMO, Inc.

Recro Pharma to Present at the 28th Annual ROTH Conference

MALVERN, Pa., March 07, 2016 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company developing multiple non-opioid therapeutics for the treatment...
February 16, 2016 08:00 ET | Source: Societal CDMO, Inc.

Recro Pharma Appoints Fred Graff as Chief Commercial Officer

MALVERN, Pa., Feb. 16, 2016 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company developing multiple non-opioid therapeutics for the treatment...
February 01, 2016 08:00 ET | Source: Societal CDMO, Inc.

Recro Pharma Initiates Second Pivotal Phase III Clinical Trial of IV Meloxicam for Acute Postoperative Pain

MALVERN, Pa., Feb. 01, 2016 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company developing multiple non-opioid therapeutics for the...
January 27, 2016 08:00 ET | Source: Societal CDMO, Inc.

Recro Pharma Initiates Pivotal Phase III Clinical Trial of IV Meloxicam for Acute Postoperative Pain

MALVERN, Pa., Jan. 27, 2016 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company developing multiple non-opioid therapeutics for the...
January 14, 2016 13:19 ET | Source: Societal CDMO, Inc.

Recro Pharma to Present at NobleCon12 Investor Conference

MALVERN, Pa., Jan. 14, 2016 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company developing multiple non-opioid therapeutics for the...
January 06, 2016 07:00 ET | Source: Societal CDMO, Inc.

Recro Pharma Reports Positive Top-Line Results for Phase II Clinical Trial of IV Meloxicam

IV Meloxicam Well Tolerated with Statistically Significant Analgesic Effect Reported Company on Track to Initiate Pivotal Phase III in 1Q 2016 MALVERN, Pa., Jan. 06, 2016 (GLOBE NEWSWIRE) --...
December 02, 2015 07:00 ET | Source: Societal CDMO, Inc.

Recro Pharma Appoints Stewart McCallum, MD, as Chief Medical Officer

MALVERN, Pa., Dec. 2, 2015 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company developing multiple non-opioid therapeutics for the treatment of...